We expect to achieve the following goals: (1) the multi-target conjugate BC-05 will keep increasing the CD13 inhibitory activity of ubenimex; (2) BC-05 will display inhibitory activity of the proteasome, which increases the anti-proliferation efficacy of the CD13 inhibitor; (3) in addition to the cytotoxicity, BC-05 will establish better anti-metastasis and immune-stimulating efficacy due to the inhibition of CD13, which may be beneficial to its in vivo anti-tumor activity. Here, ANPEP is linked to neoplasm.